ClinicalTrials.gg

Program

PF-07261271

A development code.

In Pfizer's pipeline, p40/TL1A bispecific. Its studies are mostly in Inflammatory Bowel Diseases, led by Pfizer.

Furthest: phase 1, since Sep 7, 20221 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer10 open or runningphase 1since Sep 7, 2022Sep 7, 2022none ahead
  • Named in Pfizer’s own pipeline as PF-07261271, phase 2, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2022First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT05536440 · 35 enrolled · United States

TargetBeta

“p40/TL1A bispecific”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05536440Inflammatory Bowel Diseases · United States1CompletedFeb 29, 202435

How it is read

Names in the registry

  • “PF-07261271”, 1 entry

Codes read as this program: PF07261271.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.